Table 1.
IFN-β is a tolerogenic adjuvant.
| Figurea | Group | Incidence | Attrition | Mean (± SE) cumulative scores |
P value | Mean (± SE) maximal scores |
P value | % maximal weight loss |
P value |
|---|---|---|---|---|---|---|---|---|---|
| 1A, B | IFNβ-MOG | 7 of 8 | 0 of 8 | 57.9 ± 21.6 | * | 1.6 ± 0.5 | * | 17.0 ± 3.5% | * |
| 1A, B | IFNβ + MOG | 8 of 8 | 1 of 8 | 125.9 ± 15.2 | ns | 3.5 ± 0.4 | 0.023 | 22.0 ± 3.5% | ns |
| 1A, B | MOG35-55 | 8 of 8 | 0 of 8 | 138.3 ± 19.9 | 0.024 | 3.6 ± 0.4 | 0.006 | 23.9 ± 2.4% | ns |
| 1A, B | Saline | 8 of 8 | 0 of 8 | 163.3 ± 3.8 | 0.001 | 4.0 ± 0.0 | 0.001 | 27.7 ± 1.6% | ns |
| 1C, D | IFN-β + MOG in Alum | 4 of 4 | 0 of 4 | 23.6 ± 7.8 | * | 2.0 ± 0.0 | * | 15.3 ± 3.4% | * |
| 1C, D | MOG in Alum | 4 of 4 | 1 of 4 | 61.8 ± 3.9 | 0.014 | 4.1 ± 0.3 | 0.010 | 30.6 ± 4.3% | 0.037 |
| 1C, D | Saline in Alum | 5 of 5 | 4 of 5 | 57.9 ± 5.3 | 0.034 | 4.7 ± 0.3 | 0.001 | 28.7 ± 3.1% | 0.054 |
| 1E, F | IFN-β + MOG in Alum | 7 of 13 | 0 of 13 | 9.1 ± 3.9 | * | 1.0 ± 0.4 | * | 8.5 ± 1.6% | * |
| 1E, F | IFN-β + MOG in Saline | 8 of 8 | 5 of 8 | 31.0 ± 5.1 | 0.022 | 4.1 ± 0.1 | < 0.001 | 20.3 ± 1.5% | 0.002 |
| 1E, F | MOG in Alum | 7 of 7 | 4 of 7 | 30.5 ± 3.5 | 0.013 | 4.3 ± 0.3 | < 0.001 | 16.4 ± 2.7% | ns |
| 1E, F | Saline in Alum | 5 of 5 | 5 of 5 | 23.1 ± 3.0 | ns | 5.0 ± 0.0 | < 0.001 | 21.2 ± 1.5% | 0.005 |
| 1E, F | Saline | 10 of 10 | 8 of 10 | 21.7 ± 5.5 | ns | 3.9 ± 0.4 | < 0.001 | 22.2 ± 2.6% | < 0.001 |
| 3A–B | MOG-MOG | 6 of 7 | 0 of 7 | 16.5 ± 4.8 | * | 2.4 ± 0.6 | * | 4.7 ± 2.9% | * |
| 3A–B | MOG-MOG (Anti-CD25) | 7 of 7 | 3 of 7 | 46.9 ± 2.5 | 0.002 | 4.1 ± 0.2 | 0.001 | 19.2 ± 2.3% | 0.001 |
| 3A–B | PLP-MOG | 5 of 5 | 3 of 5 | 45.3 ± 5.4 | 0.002 | 4.2 ± 0.2 | < 0.001 | 21.1 ± 3.6% | 0.001 |
| 3A–B | PLP-MOG (Anti-CD25) | 6 of 6 | 3 of 6 | 46.9 ± 2.7 | 0.003 | 4.1 ± 0.2 | 0.001 | 20.9 ± 1.5% | 0.001 |
| 3C–D | MOG-PLP | 5 of 5 | 2 of 5 | 81.1 ± 2.5 | 0.000 | 4.3 ± 0.3 | 0.004 | 17.0 ± 1.8% | 0.009 |
| 3C–D | MOG-PLP (Anti-CD25) | 5 of 5 | 3 of 5 | 65.0 ± 4.1 | ns | 4.4 ± 0.4 | 0.003 | 17.1 ± 3.3% | 0.009 |
| 3C–D | PLP-PLP | 3 of 5 | 0 of 5 | 11.1 ± 10.6 | * | 0.8 ± 0.6 | * | 3.8 ± 0.6% | * |
| 3C–D | PLP-PLP (Anti-CD25) | 5 of 5 | 1 of 5 | 68.2 ± 7.8 | 0.016 | 3.9 ± 0.3 | 0.028 | 15.3 ± 3.1% | 0.026 |
| 5A–B | IFNβ-Tregs | 2 of 8 | 0 of 8 | 1.8 ± 1.4 | * | 0.2 ± 0.1 | * | 1.0 ± 0.8% | * |
| 5A–B | Control T cells | 10 of 10 | 0 of 10 | 30.0 ± 4.6 | < 0.001 | 2.7 ± 0.2 | < 0.001 | 11.3 ± 2.5% | 0.030 |
| 5A–B | Saline | 11 of 11 | 1 of 11 | 24.4 ± 3.5 | < 0.001 | 2.9 ± 0.4 | < 0.001 | 11.9 ± 2.5% | 0.016 |
a
These data are portrayed graphically in Figures 1, 3, and 5A–B. The experimental approach is described in the respective figure legend. For Figure 3, group designations MOG-MOG, PLP-MOG, MOG-PLP, PLP-PLP refers first to the peptide (MOG35-55 or PLP178-191) in the Alum + IFN-β tolerogenic vaccine and second to the peptide in the CFA challenge. Nonparametric ANOVA based on ranked scores was used to assess group differences in mean cumulative scores and mean maximal scores, and parametric ANOVA was used to assess group differences in percent maximal weight loss relative to the comparator group
*
(Bonferroni Post-Hoc test).